European Pharmaceutical Review

FEBRUARY 2, 2024

The ATLab (Alpha Therapy Laboratory) Valenciennes in Onnaing, France, will produce lead-212 radioligand therapies. Orano Med (a subsidiary of the Orano Group), has begun to build a new manufacturing site for targeted alpha therapies (TAT) for oncology indications.

Manufacturing 98

Manufacturing Distribution Leads Pharmaceutical 98

European Pharmaceutical Review

NOVEMBER 7, 2024

percent between 2025 and 2030. Regional trends in the single-use technology rocking bioreactor market The report named the Americas as the leading region in the single-use technology rocking bioreactor market. A driving force for this was identified to be that the region benefits from having major bioreactor manufacturers.

Marketing 52

Marketing Manufacturing Medicine Leads 52

European Pharmaceutical Review

OCTOBER 22, 2024

The agency anticipated that the regulation could become law in Summer 2025. Introduction of this framework was originally announced by the MHRA in January 2023. It follows a consultation with stakeholders in 2021, which resulted in great support for proposals for a framework focused on point of care and modular manufacturing.

Medicine 52

Medicine Manufacturing Safety Consulting 52

European Pharmaceutical Review

NOVEMBER 21, 2023

If successful this could lead to regulatory submissions in 2025, supporting the health of asthma and COPD patients and making a significant positive impact on our transition to a more environmentally sustainable future,” GSK’s Chief Executive Officer, Emma Walmsley commented.

Manufacturing 116

Manufacturing Patients Pharma Leads 116

Pharmaceutical Technology

JUNE 7, 2023

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%

Leads 98

Leads Marketing FDA Sales 98

European Pharmaceutical Review

DECEMBER 22, 2022

Construction of MITC is expected to commence in early 2023, with the first mRNA vaccine expected to be produced in the UK in 2025. Steve Barclay, Health and Social Care Secretary added: “By boosting our onshore vaccine manufacturing capability, we are a step closer to becoming the leading global hub for life sciences.

Manufacturing 131

Manufacturing Government Leads Pharmaceutical 131

Pharmaceutical Technology

MAY 19, 2023

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028. EYP-1901 is an investigational sustained delivery intravitreal anti-VEGF treatment which is now being evaluated in Phase II clinical trials.

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical Food Sales 52

Nixon Gwilt Law

MARCH 19, 2024

Download the 8 Guiding Principles for AI-Driven Digital Health now!

Government 52

Government Leads 52

Nixon Gwilt Law

MARCH 19, 2024

Download the 8 Guiding Principles for AI-Driven Digital Health now!

Government 52

Government Leads 52

Pharma Marketing Network

NOVEMBER 15, 2024

By understanding your audience, balancing content, engaging transparently, using influencers, and continuously analyzing performance, your social media strategy will be primed for success in 2025. What are the top platforms for pharma marketing in 2025? LinkedIn and Twitter are leading platforms for professional and medical content.

Media 52

Media Pharma Marketing Medical 52

PM360

OCTOBER 8, 2024

First of its kind, in-office, digital hub enhances provider efficiency and care team collaboration Cincinnati, Ohio – October 7, 2024 – PatientPoint® a leading digital health company, today showcased the transformation of its healthcare professional solution with the launch of an interactive, in-office digital hub.

Healthcare Provider 52

Healthcare Provider Pharma reps Pharma Rep Physicians 52

Clarivate

AUGUST 7, 2024

OptumRx Clear Trend Guarantee (effective from January, 2025) Value-based care model; Combines guarantee and consolidates costs for retail pharmacy, home delivery, specialty drugs, and rebates into a single per-member cost. The pricing estimates are not guaranteed, leading to potential unexpected expenses.

Retail 59

Retail Marketing Competition Biopharma 59

pharmaphorum

NOVEMBER 9, 2022

A recent report from GlobalData noted that AI is being used to enhance computer-aided drug design (CADD) in a bid to reduce the time and costs involved in getting new drugs to market, and predicted that pharma spending on AI drug discovery would hit $3 billion in 2025. Its lead indication is idiopathic pulmonary fibrosis. The Pharma.AI

Pharma 104

Pharma Leads Marketing Medicine 104

pharmaphorum

OCTOBER 9, 2022

UK-based PureTech – which develops its own therapies and also has interests in a wide range of companies including digital health players Akili and Sonde as well as drug developers Vedanta, Gelesis and Follica – said it has “exchanged indicative, non-binding proposals” with Nektar that have no guarantee of leading to a deal.

Leads 59

Leads Healthcare Healthcare 59

European Pharmaceutical Review

NOVEMBER 23, 2023

For example, CPI asserted that lead times for clinical trial materials are hindering new therapies being developed. CPI confirmed that the centre will establish operations during 2024 and be finished in late 2025. This is a first-of-its-kind collaboration for the pharma industry.

Manufacturing 104

Manufacturing Medicine Government Pharmaceutical 104

Pharmaceutical Technology

SEPTEMBER 5, 2022

Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”. On 23 August, at a Reuters Newsmakers online forum, Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025.

FDA 114

FDA Pharmaceutical Biopharma Pharma 114

European Pharmaceutical Review

SEPTEMBER 26, 2022

The €60 million expansion will open 70 new jobs in sterile manufacturing, quality control and engineering in 2025. to lead R&D organization and drive continued pipeline advancement… The post AbbVie Cork facility €60 million expansion appeared first on European Pharmaceutical Review. AbbVie announces Michael Severino, M.D.

Manufacturing 98

Manufacturing Pharmaceutical manufacturing Biopharma Engineering 98

Pharmaceutical Technology

JUNE 20, 2023

“It will be an iconic addition to the world-leading Melbourne biomedical precinct and will equip us with the facilities and resources we need to get ahead of the next pandemic.” Demolition of the existing buildings on the site will commence next year, and construction work on the new building will begin in 2025.

Government 52

Government Leads 52

Clarivate

MAY 13, 2024

After staying relatively flat for several years, enrollment growth took off in 2021 after an expansion in federal subsidies for silver-level plans passed in the American Rescue Plan and was then renewed through 2025 in the Inflation Reduction Act. Pillo, Senior Healthcare Research and Data Analyst. The post The U.S.

Insurance 52

Insurance Marketing Healthcare Healthcare 52

European Pharmaceutical Review

MARCH 6, 2023

Harwell, the UK’s leading science and innovation campus in Oxfordshire will be the location of the Moderna Innovation and Technology Centre (MITC). The Moderna Innovation and Technology Centre is expected to become operational in 2025. Moderna is the latest organisation to join Harwell’s Health Tech cluster.

Manufacturing 98

Manufacturing Food and Drug Administration Government Food 98

Pharmaceutical Technology

JUNE 8, 2023

Mendus has entered an alliance with NorthX Biologics to co-establish a cell therapy manufacturing unit for its lead asset, vididencel, in Sweden. The cell therapy facility will be used for the large-scale production of vididencel, Mendus’s lead programme. All operations will take place there until the second quarter of 2025.

Manufacturing 52

Manufacturing Leads Patients Medicine 52

PM360

OCTOBER 25, 2023

According to a report by McKinsey & Company, the medical affairs function is on track to rise in importance, becoming the third strategic pillar alongside the research and development (R&D) and commercial functions by 2025. This lack of understanding may lead to resistance or wariness of new technology. Regulatory concerns.

Management 105

Management Medical Pharma Pharmaceutical 105

Pharmaceutical Technology

APRIL 17, 2023

The proposed merger is expected to realise at least $50m of net transaction cash proceeds, set to be used to finance the merged entity’s business as well as Phase II trials and operations through the second quarter of 2025. The merger is scheduled to be completed by the third quarter of 2023.

Patients 98

Patients Leads Pharmaceutical Marketing 98

Pharmaceutical Technology

DECEMBER 21, 2022

Planned to be operational by 2025, the construction of the facility is anticipated to begin early next year. Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.

Government 140

Government Manufacturing Pharmaceutical Marketing 140

pharmaphorum

JANUARY 9, 2023

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50

Pharma 87

Pharma Biopharma Management Medicine 87

MedTechVets

OCTOBER 29, 2024

” A Look Ahead: 2025 and Beyond During the panel, Steve Mapa reflected on the program’s current success and exciting future: “We currently have around 100 active mentors—thank you to each one of you. Mentors are the heart and soul of our program, and our goal for 2025 is to grow that number to 150.”

Consulting 59

Consulting Networking Government Medical 59

pharmaphorum

SEPTEMBER 14, 2022

SparingVision’s lead candidates are both targeting inherited retinal diseases (IRDs), a group which already has a gene therapy on the market in Novartis’ Luxturna (voretigene neparvovec), which was approved by the FDA in 2017 for biallelic RPE65 mutation-associated retinal dystrophy, a group which includes a small group of RP patients.

Safety 52

Safety Leads Patients FDA 52

Pharmaceutical Technology

MAY 2, 2023

Marker Therapeutics CEO Juan Vera stated: “Marker’s management and impartial members of the board worked with John Wilson and CellReady to develop a very creative and non-dilutive plan that provides Marker with the financial runway to pursue its clinical priorities through the end of 2025. “At

Manufacturing 52

Manufacturing Leads Management Pharmaceutical 52

Pharmaceutical Technology

JANUARY 19, 2023

Antigens such as CD123 and CD33, despite being markers of myeloid cells, are shared with their healthy counterparts, and myeloablation following their depletion often leads to detrimental clinical outcomes. A lack of good antigens to target in AML is widely believed to have caused this dearth of effective cell therapies.

Marketing 52

Marketing FDA Sales Management 52

pharmaphorum

OCTOBER 26, 2022

The drug was highlighted at Boehringer’s R&D update earlier this year as one of the most promising candidates among 15 new medicines it plans to bring to market by 2025, fuelled by a €25 billion R&D spend. There are more than 200 lung disorders that can lead to pulmonary fibrosis.

Recruitment 95

Recruitment Prospecting Marketing Patients 95

European Pharmaceutical Review

AUGUST 1, 2022

Therefore, it is essential that we broaden the scope of medical trials and research,” commented Tinamarie Duff, DAWN Global People & Business Resource Group Lead. Common clinical trial practices exclude up to a quarter of the US population based on disability status, according to BMS.

Food and Drug Administration 122

Food and Drug Administration Medical Medicine Engineering 122

Pharmaceutical Technology

MAY 5, 2023

The facility will be situated with DiNAMIQS’ existing operations at Bio-Technopark in Zurich-Schlieren, Switzerland, and is anticipated to become operational in 2025. Siegfried will leverage DiNAMIQS’ capabilities to commercial scale by constructing a facility that complies with good manufacturing practice standards.

Leads 52

Leads Manufacturing Management Pharmaceutical 52

pharmaphorum

SEPTEMBER 21, 2022

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. billion or more.

Sales 109

Sales Patients Biopharma Medicine 109

Pharmaceutical Technology

JANUARY 30, 2023

Comirnaty, which was first approved in the UK by an Emergency Use Approval (EUA) from the Medicines and Healthcare products Regulatory Agency (MHRA) on December 2, 2020, is currently the leading prophylactic vaccine with 2021 sales of $41.5 Likewise, Moderna’s Spikevax, the second leading COVID-19 vaccine with 19.5

Sales 52

Sales Leads Competition Medicine 52

Pharmaceutical Technology

AUGUST 11, 2022

The proceeds from the business combination will be utilised to advance the pipeline of Disc to clinical trials and offer funding into 2025. Present Disc Medicine CEO and president John Quisel will lead the merged company along with other management team members. It will be valued at nearly $175m in cash or cash equivalents.

Medicine 59

Medicine Transportation Patients Healthcare 59

pharmaphorum

JULY 22, 2022

Co-Chaired by: Conor Murray, Chairman, Irish Cleanroom Society and Connor McMorrow, Aseptic Lead Cell Therapy, Takeda. In 2025, the global cleanroom technology market is expected to reach nearly $5 billion. Sponsored by Ecolab, Elis Cleanroom, Innerspace, Microgenetics, Novatek. Advances in Pharma 4.0

Pharmaceutical 52

Pharmaceutical Management Engineering Media 52

European Pharmaceutical Review

MARCH 14, 2024

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Topline data from Vera’s ORIGIN Phase III trial of atacicept is expected in the first half of 2025. IgAN is the most common primary glomerulonephritis worldwide.

Food and Drug Administration 98

Food and Drug Administration Leads Patients Side effects 98